Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
AbSci Corp (Absci) is a generative AI drug creation company that develops biologics through innovative AI-driven processes. It offers SoluPro, a genetically engineered semi-oxidizing cytoplasm and a dual inducible promoter system that enables scalable production of antibodies, antibody fragments and other soluble recombinant proteins. Absci's products are utilized by pharmaceutical, technology, and academic partners to address complex diseases, including inflammatory bowel disease and oncology. The company provides its proteins and antibodies in the areas of cancer, hormone, autoimmune and blood disorder therapies. Absci is headquartered in Vancouver, Washington, the US.
Headquarters
United States of America
Address
18105 Se Mill Plain Blvd, Vancouver, Washington, 98683
Website
www.absci.com
Telephone
1 302 6587581
No of Employees
140
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABSI (NASD)
Revenue (2024)
$2.8M
-38.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-11.7%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
-80.9%
(2024 vs 2023)
* As of and is in US$
AbSci Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | SoluPure |
| ABS-101: Inflammatory Bowel Disease | SoluPro |
| ABS-201: Androgenic Alopecia | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In January, the company entered into a partnership with Invetx to develop an innovative Half-Life Extension platform for animal health applications. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Almirall to develop and commercialize AI-designed therapeutics for chronic and debilitating skin diseases. |
| 2023 | Contracts/Agreements | In May, the company entered into an agreement with University of Oxford’s Kennedy Institute of Rheumatology, to create breakthrough therapies for immune-mediated diseases. |
Competitor Comparison
| Key Parameters | AbSci Corp | Catalent Inc | Akron Biotechnology LLC | Axcella Health Inc (Inactive) | Bikam Pharmaceuticals Inc (Inactive) |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Vancouver | Somerset | Boca Raton | Cambridge | Lexington |
| State/Province | Washington | New Jersey | Florida | Massachusetts | Massachusetts |
| No. of Employees | 140 | 16,900 | - | 11 | - |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sean McClain | Chief Executive Officer; Director | Executive Board | - | - |
| Zach Jonasson | Chief Business Officer; Chief Financial Officer | Senior Management | - | - |
| Todd Bedrick | Chief Accounting Officer | Senior Management | - | - |
| Shelby Walker | Chief Legal Officer | Senior Management | - | - |
| Karin Wierinck | Chief People Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer